Experimental Gene Therapy for Fanconi Anemia Earns Fast Track and Regenerative Medicine Advanced Therapy Designation
<a href="https://pixabay.com/users/PublicDomainPictures/">PublicDomainPictures</a> / Pixabay

Experimental Gene Therapy for Fanconi Anemia Earns Fast Track and Regenerative Medicine Advanced Therapy Designation

According to a story from BioPortfolio, the gene therapy company Rocket Pharmaceuticals has recently announced that the company's investigational gene therapy RP-L102 has earned both Fast Track and Regenerative Medicine…

Continue Reading
This Company Will Work With Nonprofit Organizations to Develop New Treatment for Epidermolysis Bullosa
<a href="https://pixabay.com/users/DarkoStojanovic/">DarkoStojanovic</a> / Pixabay

This Company Will Work With Nonprofit Organizations to Develop New Treatment for Epidermolysis Bullosa

According to a story from PR Newswire, the biopharmaceutical company Constant Pharmaceuticals recently announced that it plans to develop its experimental compound TXA127 as a therapy for epidermolysis bullosa (EB).…

Continue Reading
Close Menu